Delivering big-bang growth

Lupin tops the list of super stocks with multibagger gains that can give any mid-cap multibagger a run for its money. If you had invested ₹10,000 in Lupin ten years ago, you would have a cool ₹2.69 lakh today. That's 27 times your investment. Lupin, the specialist in anti-TB therapy, is now a diversified pharma company that ranks eighth in the domestic market. It caters to the chronic therapies for the cardio-vascular system (CVS), diabetes, respiration and the central nervous system (CNS). Lupin still leads in the anti-TB market with a 53 per cent market share and ranks third in

This article was originally published on December 09, 2015.